BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia - Hurtz, Christian; Hatzi, Katerina; Cerchietti, Leandro; Braig, Melanie; Park, Eugene; Kim, Yong-mi; Herzog, Sebastian; Ramezani-Rad, Parham; Jumaa, Hassan; Müller, Martin C.; Hofmann, Wolf-Karsten; Hochhaus, Andreas; et al. (The Journal of experimental medicine, 2011)
Keywords: Animals; Antigens, CD34 - metabolism; Benzamides; Brief Definitive Report; Cell Survival; Disease Models, Animal; DNA-Binding Proteins - antagonists & inhibitors; DNA-Binding Proteins - genetics; DNA-Binding Proteins - metabolism; Forkhead Transcription Factors - metabolism; Hematopoietic Stem Cells - cytology; Hematopoietic Stem Cells - physiology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells - physiology; Piperazines - therapeutic use; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - antagonists & inhibitors; Proto-Oncogene Proteins c-bcl-6; Pyrimidines - therapeutic use; Tumor Cells, Cultured; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism